From Breast Cancer Screening to Definitive Diagnosis: Strategies for Successfully Serving the Underserved

November 2011 Vol 2, No 6
Dawn Parsons, RN, OCN
Diana Phillips, MAHS
Joni Watson, MSN, RN, OCN

Significance: Uninsured patients receive half the care of their insured counterparts, leading to poorer health outcomes as a result of delayed diagnoses. Breaks in cancer care impact survival rates and quality of life. The Seton Healthcare Family, the only NCI Community Cancer Centers Program (NCCCP) site in the Southwest, has provided breast cancer care spanning the full cancer continuum to low-income and uninsured women across Central Texas since 1987.

Objectives: This presentation discusses Seton’s successful efforts to expand culturally appropriate breast cancer outreach to high-risk, diverse, and underserved women residing in Central Texas, focusing on factors supporting navigation of women with an abnormal screening result to definitive diagnosis in a timely manner with a lost-to-follow-up rate less than 1%.

Methods: Seton’s mobile mammography program, with support from Komen for the Cure Austin and the National Breast Cancer Foundation, couples screening mammography with breast health education and clinical breast exam by specially trained RNs. By offering culturally appropriate, free breast services in partnership with respected community sites, Seton provides accessible services to underserved women in their communities. Women with abnormal results are navigated to definitive diagnosis by the same screening RN. Detailed protocols and breast diagnostics funding facilitate compliance with diagnostic testing. Multiple reminder efforts encourage yearly screening participation per national guidelines.

Results: From April 1, 2010, to March 31, 2011, 1828 women were screened at 121 sites in 7 federally designated medically underserved counties, with 56% of participants Hispanic, 26% non-Hispanic Caucasian, 13% Asian, and 5% African-American. A total of 203 women had an abnormal result, and all were navigated to a definitive diagnosis. Grants covered costs of nearly 700 diagnostic procedures and more than 300 physician office visits. Women progressed from abnormality detection to definitive diagnosis in an average of 24 days. The program also averages a 38% screening return rate over the past 5 years.

Conclusions: Seton’s breast cancer screening program is a community-centric initiative focused on long-term health behavior changes based on trust developed through community linkages, removal of financial barriers, effective processes, and consistent relationships between clients and skilled RN navigators. As a result of the success of the screening model, Seton has developed programs replicating that same model for other types of disease-specific screenings (cervical and skin) for high-risk underserved populations. Seton’s model has been shared with other NCCCP sites and is replicable by other organizations.

Related Articles
Key Breast Cancer Abstracts in 2023 and Innovations in Ovarian Function Suppression:
Matteo Lambertini, MD, PhD, Erica Stringer-Reasor, MD, Director, Sara M. Tolaney, MD, MPH
Video Library
Please join Sara Tolaney, MD, MPH, Dana-Farber Cancer Center, Boston, MA; Erica Stringer-Reasor, MD, University of Alabama, Birmingham; and Matteo Lambertini, MD, PhD, University of Genoa, Italy, as they provide expert commentary on key breast cancer abstracts presented at the 2023 ASCO Annual Meetings that will impact young women with ER+/HER2- breast cancer.
Assessment of Side Effects (SEs) Impacting Quality of Life (QOL) in Patients (Pts) Undergoing Treatment (tx) for Advanced Breast Cancer (ABC) in Clinical Practice: A Real-World (RW) Multicountry Survey
November 2022 Vol 13, No 11
To examine how SEs impacting QOL in pts with ABC are perceived.
Intracranial Activity of Tepotinib in Patients with MET Exon 14 (METex14) Skipping Non–Small-Cell Lung Cancer (NSCLC) Enrolled in VISION
November 2022 Vol 13, No 11
To provide analysis of the intracranial activity of tepotinib in patients with METex14 skipping NSCLC with BM from the VISION study to aid oncology nurse navigators who manage this population of patients.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State